The growing interest in legal LSD alternatives has led to the development of various analogs, each with subtle chemical differences but similar core functions. Among the most researched are 1P-LSD, 1D-LSD, 1V-LSD, and 1S-LSD. While all of these compounds are lysergamides and act as prodrugs of LSD, their structural modifications affect legal status, potency, and onset.
1P-LSD was one of the first legal LSD alternatives, featuring a propionyl group. It closely mimics LSD-25 in effects and duration. 1V-LSD introduced a valeryl group and is thought to have a slower onset and milder effects. 1D-LSD was a commercial successor to 1V-LSD after regulatory updates.
1S-LSD, the newest analog, contains a silicon-based trimethylsilyl group. This structural shift is not only pharmacologically significant but also strategically designed to bypass legal restrictions like those in Germany’s NpSG. 1S-LSD is currently a legal LSD variant, making it highly attractive to research institutions.
While all these analogs share a common mechanism of action—primarily interacting with the 5-HT2A receptor—they differ in terms of absorption rates, duration of action, and legal status. Understanding these differences is key to choosing the right compound for scientific purposes.